Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash & Equivalents: 2017-2024

Historic Cash & Equivalents for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $97.2 million.

  • Protagonist Therapeutics' Cash & Equivalents fell 13.28% to $113.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.7 million, marking a year-over-year decrease of 13.28%. This contributed to the annual value of $97.2 million for FY2024, which is 47.92% down from last year.
  • As of FY2024, Protagonist Therapeutics' Cash & Equivalents stood at $97.2 million, which was down 47.92% from $186.7 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Cash & Equivalents ranged from a high of $186.7 million in FY2023 and a low of $97.2 million during FY2024.
  • Over the past 3 years, Protagonist Therapeutics' median Cash & Equivalents value was $125.7 million (recorded in 2022), while the average stood at $136.6 million.
  • In the last 5 years, Protagonist Therapeutics' Cash & Equivalents spiked by 255.57% in 2020 and then slumped by 47.92% in 2024.
  • Protagonist Therapeutics' Cash & Equivalents (Yearly) stood at $117.4 million in 2020, then increased by 5.37% to $123.7 million in 2021, then climbed by 1.68% to $125.7 million in 2022, then surged by 48.50% to $186.7 million in 2023, then crashed by 47.92% to $97.2 million in 2024.